<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823431</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00071589</org_study_id>
    <nct_id>NCT02823431</nct_id>
  </id_info>
  <brief_title>Effect of Urethral Analgesia on Voiding</brief_title>
  <official_title>Contribution of Urethral Sensory Feedback in Voiding Efficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how urethral analgesia impacts voiding efficiency in&#xD;
      healthy women. The investigator hypothesizes that anesthetizing the urethral with lidocaine&#xD;
      gel will decrease voiding efficiency as measured by standard bladder testing (urodynamic&#xD;
      testing).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Purpose of the Study The purpose of this study is to determine whether urethral sensory&#xD;
           feedback has a role in the micturition (bladder emptying) reflex in female controls&#xD;
           during routine office Urodynamic Studies (UDS). UDS are current clinical tests of&#xD;
           urethral and bladder function and consist of several individual studies including&#xD;
           filling cystometry, pressure-flow studies, and urethral pressure profilometry (UPP).&#xD;
           Filling cystometry focuses primarily on sensation and activity of the bladder during the&#xD;
           filling (or storage) phase of the micturition (voiding) cycle. Pressure-flow studies&#xD;
           (which include voiding cystometry) are used to assess the motor activity of the bladder&#xD;
           muscle during bladder emptying. UPP assesses urethral sphincter motor function and has&#xD;
           traditionally been used to evaluate stress urinary incontinence. Perineal patch&#xD;
           electromyography (EMG) is often added to UDS to assess for pelvic floor muscle&#xD;
           recruitment during voiding, which may suggest voiding dysfunction.&#xD;
&#xD;
        2. Background &amp; Significance The storage and elimination of urine is regulated by neural&#xD;
           circuits in the brain and spinal cord to coordinate function between the urinary bladder&#xD;
           and the urethra. During the micturition (bladder emptying) reflex, the elimination of&#xD;
           urine is facilitated by bladder wall contraction and urethral wall and pelvic floor&#xD;
           muscle relaxation. Urine that subsequently flows through the urethra also activates&#xD;
           sensory nerves to amplify bladder contractions and maintain efficient bladder emptying.&#xD;
           Incomplete voiding and urinary retention occurs when these mechanisms are disrupted or&#xD;
           poorly coordinated.&#xD;
&#xD;
           Incomplete bladder emptying due to detrusor underactivity is an understudied health&#xD;
           concern for women in the United States. The overall incidence detrusor underactivity in&#xD;
           women has not yet been reported in the literature. One study by Wu et al. (2005)&#xD;
           determined that 7.8% of patients in an outpatient rehabilitation facility had symptoms&#xD;
           of incomplete bladder emptying; whereas, 21% of people without symptoms had elevated&#xD;
           post void residuals when universally screened. Their population consisted of 350&#xD;
           patients, of which two-thirds were women. Lower urinary tract symptoms, including&#xD;
           urinary urgency, frequency and incomplete bladder emptying, have been shown to decrease&#xD;
           quality of life, increase healthcare utilization, decrease workplace productivity, and&#xD;
           impact intimate relationships.&#xD;
&#xD;
           The current clinical management options for women with retention are intermittent or&#xD;
           indwelling catheterization, urethral dilation, or reconstructive surgery. These&#xD;
           treatments, however, often fail to completely resolve lower urinary tract symptoms and&#xD;
           the patients may develop chronic retention complications such as overflow incontinence,&#xD;
           hydroureter, hydronephrosis, infection, or renal failure. In order to improve&#xD;
           therapeutic outcomes, there is still a need to clarify the specific mechanisms that&#xD;
           underlie detrusor underactivity in women. Our proposed studies will be contributing to&#xD;
           the growing body of literature implicating urethral sensory feedback as a candidate to&#xD;
           recover efficient bladder emptying.&#xD;
&#xD;
        3. Hypothesis and Justification Overall Hypothesis: Urethral afferent nerve fiber&#xD;
           activation augments bladder contractions for efficient voiding and urethral anesthesia&#xD;
           will disrupt sensory feedback and impair bladder emptying.&#xD;
&#xD;
           Specific Aim 1: To assess voiding efficiency (voided volume/{voided volume + residual&#xD;
           volume}) in women controls with and without urethral anesthesia Hypothesis 1a: Voiding&#xD;
           efficiency will be lower when the urethra is anesthetized during micturition&#xD;
           pressure-flow studies Hypothesis 1b: Detrusor contraction at maximum flow rate&#xD;
           (Pdet@Qmax) and duration of detrusor contraction will be reduced when the urethra is&#xD;
           anesthetized during micturition pressure-flow studies Hypothesis 1c: Voiding while&#xD;
           anesthetized will lead to increased valsalva-voiding (increased intra-abdominal&#xD;
           pressure, Pabd) and an intermittent urinary stream during micturition pressure-flow&#xD;
           studies&#xD;
&#xD;
           Specific Aim 2: To assess whether urethral anesthesia gel improves discomfort during the&#xD;
           UDS Hypothesis: Visual Analog Scale (VAS) scores for pain will be lower during the UDS&#xD;
           when the urethra has been anesthetized&#xD;
&#xD;
           Studies supporting Specific Aims:&#xD;
&#xD;
           i. Micturition with Urethral Anesthesia Distension and fluid flow in the urethra has&#xD;
           been previously demonstrated to evoke sensory nerve discharge. Nerve firing originating&#xD;
           from the urethra is then able to initiate contractions in the filling bladder and&#xD;
           increase the amplitude and duration of ongoing bladder contractions. This&#xD;
           pudendal-bladder reflex has been shown to be necessary for efficient bladder emptying&#xD;
           because disruption to urethral sensory feedback by transection of the sensory branch of&#xD;
           the pudendal nerve or intraurethral anesthesia reduces voiding efficiency in the rat.&#xD;
           Urethral anesthesia in humans has also been demonstrated to increase post void residual&#xD;
           and alter symptoms experienced during the voiding phase.&#xD;
&#xD;
           This investigator's approach is novel as this study will characterize voiding in healthy&#xD;
           women who will be randomized to placebo versus urethral analgesia. Investigators will do&#xD;
           this by performing UDS, which will include all clinical tests for bladder function, with&#xD;
           or without urethral anesthesia (2% lidocaine hydrochloride jelly or plain aqueous gel).&#xD;
&#xD;
           ii. Pain Perception During Catheterization Urethral catheterization elicits mild to&#xD;
           moderate pain in women. The use of lubricant anesthetic on the catheter is one available&#xD;
           option to manage tissue trauma and pain perception. Several studies have reported that&#xD;
           2% lidocaine gel reduces procedural pain during female urethral catheterization. Others&#xD;
           however, have found that lubricant anesthetic and catheter size, does not effect the&#xD;
           perception of pain in urethral catheterization in women. These discrepant reports&#xD;
           suggest a consensus has not been reached on the efficacy of lubricant anesthetic and&#xD;
           pain perception in women.&#xD;
&#xD;
        4. Subject Recruitment: Subjects will be recruited from Duke Hospital and Duke University&#xD;
           Campus via newspaper advertisements and paper fliers.&#xD;
&#xD;
        5. Design and Procedures To account for screen failures, it is anticipated that a total of&#xD;
           40 female controls will be screened to achieve n=20 for completed UDS. Subjects will&#xD;
           perform a baseline voiding test (uroflow), then will be randomized to undergoing&#xD;
           urodynamic studies with or without urethral analgesia. Participants will be randomized&#xD;
           to their arm of the study using a random number generator (MatLab). Study staff and the&#xD;
           subjects will be blinded to the treatment regimen; thus, this study design is a&#xD;
           randomized double-blind placebo-controlled trial. Inclusion and exclusion criteria are&#xD;
           listed in a separate section.&#xD;
&#xD;
      Study Visit Questionnaires and Tests After their phone screen, (3.i), participants will be&#xD;
      scheduled for the study visit. All study procedures will take place at the Duke Urogynecology&#xD;
      Office at Patterson Place. Participants will undergo informed consent on arrival to their&#xD;
      study visit. Subjects will provide a urine specimen for a point of care urinalysis and&#xD;
      pregnancy test. Pre-procedure vital signs, including height and weight will be obtained.&#xD;
      Subjects will fill out the following questionnaires: Lower Urinary Tract Symptoms Tool,&#xD;
      Sociodemographics and Functional Comorbidity Index and complete a Medication List.&#xD;
&#xD;
      If subjects have a negative urinalysis and pregnancy test they will be randomized. If either&#xD;
      of their point of care tests is positive (per exclusion criteria), they will be excluded from&#xD;
      the study and referred to their primary care physician.&#xD;
&#xD;
      Prior to performing UDS, the subject's bladder will be scanned transabdominally with a&#xD;
      standard clinic bladder scanner. This will ensure adequate urine is within the bladder to&#xD;
      start the first test.&#xD;
&#xD;
      The participant will then be placed in the dorsal lithotomy position and a pelvic exam will&#xD;
      be performed to confirm no pelvic organ prolapse past the hymen during valsalva. Uroflow&#xD;
      testing will then begin. Subjects will then undergo a 2-hour wait and be given water to&#xD;
      re-fill their bladder. After two hours, Urodynamic testing will be performed.&#xD;
&#xD;
      Order of Studies Performed During Urodynamic Testing: Complex Uroflowmetry, Complex&#xD;
      Cystometry, Urethral Pressure Profilometry, Micturition Pressure-flow Study&#xD;
&#xD;
      The Visual Analog Scale (VAS) will be administered to assess discomfort at the following&#xD;
      times; after uroflow but before PVR (baseline), immediately after the urethral catheter is&#xD;
      placed, after 100mL of fluid has been instilled, and at full bladder capacity (MCC).&#xD;
&#xD;
      After the completion of the UDS procedures, subjects will have completed their study visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Voiding Efficiency</measure>
    <time_frame>duration of urodynamic study, 2 hours</time_frame>
    <description>voided volume/{voided volume + residual volume} during micturition study during urodynamic studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detrusor Pressure at Maximum Flow</measure>
    <time_frame>duration of urodynamic study, 2 hours</time_frame>
    <description>bladder pressure reading (mmHg) during maximum flow during micturition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Interrupted Urinary Flow Pattern During Micturition</measure>
    <time_frame>duration of urodynamic study, 2 hours</time_frame>
    <description>presence of interrupted flow during micturition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Scores (Measure of Discomfort) After Catheterization</measure>
    <time_frame>duration of urodynamic study, 2 hours</time_frame>
    <description>visual analog scales were performed to evaluate discomfort at specified time points during the urodynamic studies. The scale is 1-100mm, with higher numbers indicating greater discomfort.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Urethral Analgesia</condition>
  <arm_group>
    <arm_group_label>Analgesia Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine gel</intervention_name>
    <arm_group_label>Analgesia Arm</arm_group_label>
    <other_name>Urojet 2% gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plain aqueous gel</intervention_name>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>KY gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females ages 18-60 years&#xD;
&#xD;
          -  No health conditions as indicated in exclusion criteria&#xD;
&#xD;
          -  Able to provide informed consent and agree to the risks of the study&#xD;
&#xD;
          -  Willing to abstain from caffeine and alcohol for 24 hours&#xD;
&#xD;
          -  Willing to avoid taking anticholinergic medications (for reasons other than&#xD;
             incontinence; e.g., diphenhydramine) for one week prior to the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pelvic organ prolapse past the hymen&#xD;
&#xD;
          -  Multiple sclerosis, myasthenia gravis, Parkinson's Disease, stroke within the past 6&#xD;
             months&#xD;
&#xD;
          -  Interstitial cystitis / Bladder Pain Syndrome&#xD;
&#xD;
          -  Recurrent (≥ 3/year) urinary tract infections&#xD;
&#xD;
          -  Positive pregnancy test at the time of consent&#xD;
&#xD;
          -  ≤ 6 weeks postpartum or if breastfeeding&#xD;
&#xD;
          -  Positive urine dip (&gt;+1nitrites or &gt;1+LE) and urinary symptoms at the time of consent&#xD;
&#xD;
          -  &gt;1+ blood on urinary dip&#xD;
&#xD;
          -  Morbid obesity (BMI &gt;40)&#xD;
&#xD;
          -  Taking anticholinergic medications for urinary incontinence&#xD;
&#xD;
          -  &gt;2 replies of ≥ &quot;sometimes&quot; on the Lower Urinary Tract Symptoms questionnaire at the&#xD;
             time of consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Grill</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Campus</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chen SC, Grill WM, Fan WJ, Kou YR, Lin YS, Lai CH, Peng CW. Bilateral pudendal afferent stimulation improves bladder emptying in rats with urinary retention. BJU Int. 2012 Apr;109(7):1051-8. doi: 10.1111/j.1464-410X.2011.10526.x. Epub 2011 Aug 23.</citation>
    <PMID>21883860</PMID>
  </reference>
  <reference>
    <citation>Peng CW, Chen JJ, Cheng CL, Grill WM. Improved bladder emptying in urinary retention by electrical stimulation of pudendal afferents. J Neural Eng. 2008 Jun;5(2):144-54. doi: 10.1088/1741-2560/5/2/005. Epub 2008 Apr 22.</citation>
    <PMID>18430976</PMID>
  </reference>
  <reference>
    <citation>Shafik A, Shafik AA, El-Sibai O, Ahmed I. Role of positive urethrovesical feedback in vesical evacuation. The concept of a second micturition reflex: the urethrovesical reflex. World J Urol. 2003 Aug;21(3):167-70. Epub 2003 Jul 25.</citation>
    <PMID>12898170</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <results_first_submitted>June 5, 2017</results_first_submitted>
  <results_first_submitted_qc>October 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2018</results_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>voiding efficiency</keyword>
  <keyword>detrusor underactivity</keyword>
  <keyword>urodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Analgesia Arm</title>
          <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).&#xD;
lidocaine gel</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.&#xD;
Plain aqueous gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Analgesia Arm</title>
          <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).&#xD;
lidocaine gel</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.&#xD;
Plain aqueous gel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="9.6"/>
                    <measurement group_id="B2" value="33" spread="9.2"/>
                    <measurement group_id="B3" value="31.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="3.7"/>
                    <measurement group_id="B2" value="25" spread="5"/>
                    <measurement group_id="B3" value="24" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Voiding Efficiency</title>
        <description>voided volume/{voided volume + residual volume} during micturition study during urodynamic studies</description>
        <time_frame>duration of urodynamic study, 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analgesia Arm</title>
            <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).&#xD;
lidocaine gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.&#xD;
Plain aqueous gel</description>
          </group>
        </group_list>
        <measure>
          <title>Voiding Efficiency</title>
          <description>voided volume/{voided volume + residual volume} during micturition study during urodynamic studies</description>
          <units>Percent voiding efficiency</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="8"/>
                    <measurement group_id="O2" value="90" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detrusor Pressure at Maximum Flow</title>
        <description>bladder pressure reading (mmHg) during maximum flow during micturition</description>
        <time_frame>duration of urodynamic study, 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analgesia Arm</title>
            <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).&#xD;
lidocaine gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.&#xD;
Plain aqueous gel</description>
          </group>
        </group_list>
        <measure>
          <title>Detrusor Pressure at Maximum Flow</title>
          <description>bladder pressure reading (mmHg) during maximum flow during micturition</description>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="19.2"/>
                    <measurement group_id="O2" value="31" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Interrupted Urinary Flow Pattern During Micturition</title>
        <description>presence of interrupted flow during micturition</description>
        <time_frame>duration of urodynamic study, 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analgesia Arm</title>
            <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).&#xD;
lidocaine gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.&#xD;
Plain aqueous gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Interrupted Urinary Flow Pattern During Micturition</title>
          <description>presence of interrupted flow during micturition</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale Scores (Measure of Discomfort) After Catheterization</title>
        <description>visual analog scales were performed to evaluate discomfort at specified time points during the urodynamic studies. The scale is 1-100mm, with higher numbers indicating greater discomfort.</description>
        <time_frame>duration of urodynamic study, 2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Analgesia Arm</title>
            <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).&#xD;
lidocaine gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.&#xD;
Plain aqueous gel</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Scores (Measure of Discomfort) After Catheterization</title>
          <description>visual analog scales were performed to evaluate discomfort at specified time points during the urodynamic studies. The scale is 1-100mm, with higher numbers indicating greater discomfort.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" spread="20"/>
                    <measurement group_id="O2" value="19" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the study visit and if contact was made by the participant in the 1 month following the study visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Analgesia Arm</title>
          <description>Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).&#xD;
lidocaine gel</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.&#xD;
Plain aqueous gel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Warren Grill PhD</name_or_title>
      <organization>Duke Biomedical Engineering</organization>
      <phone>(919) 660-5276</phone>
      <email>warren.grill@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

